ProKidney (ProKidney) Notes Receivable : $0.00 Mil (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is ProKidney Notes Receivable?

ProKidney's Notes Receivable for the quarter that ended in Mar. 2024 was $0.00 Mil.

ProKidney Notes Receivable Historical Data

The historical data trend for ProKidney's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProKidney Notes Receivable Chart

ProKidney Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Notes Receivable

ProKidney Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Notes Receivable	Get a 7-Day Free Trial									-	-	-	-	-

ProKidney Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

ProKidney Notes Receivable Related Terms

Thank you for viewing the detailed overview of ProKidney's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

ProKidney (ProKidney) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProKidney Corp (NAS:PROK) » Definitions » Notes Receivable

Comparable Companies

Traded in Other Exchanges

PROK:Mexico

Address

2000 Frontis Plaza Boulevard, Suite 250, Winston-Salem, NC, USA, 27103

Website

https://www.prokidney.com

ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease.

Executives

Chamath Palihapitiya	10 percent owner	THE SOCIAL-CAPITAL PARTNERSHIP, L.L.C., 506 SANTA CRUZ AVENUE, SUITE 300, MENLO PARK CA 94025
Sc Pipe Holdings Llc	10 percent owner	506 SANTA CRUZ AVE., SUITE 300, MENLO PARK CA 94025
Sc Master Holdings, Llc	10 percent owner	506 SANTA CRUZ AVENUE, SUITE 300, MENLO PARK CA 94025
Bruce Culleton	officer: EVP, Clinical Development	2000 FRONTIS PLAZA BLVD., SUITE 250, WINSTON-SALEM NC 27103
Aaron Cowen	10 percent owner	540 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Mary Weger	officer: Chief People Officer	ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142
William F Doyle	director
Tolerantia, Llc	10 percent owner	110 EAST 59TH STREET, SUITE 3300, NEW YORK NY 10022
Jimenez Santos Jose Ignacio	director	C/O PROKIDNEY CORP., 3929 WESTPOINT BLVD., SUITE G, WINSTON-SALEM NC 27103
Deepak Jain	officer: Chief Operating Officer	C/O PROKIDNEY CORP., 3929 WESTPOINT BLVD., SUITE G, WINSTON-SALEM NC 27103
Darin J. Weber	officer: SVP of Regulatory Development	C/O PROKIDNEY CORP., 3929 WESTPOINT BLVD., SUITE G, WINSTON-SALEM NC 27103
Libbie Parker Mckenzie	officer: Chief Medical Officer	C/O PROKIDNEY CORP., 3929 WESTPOINT BLVD., SUITE G, WINSTON-SALEM NC 27103
James Coulston	officer: Chief Financial Officer	C/O PROKIDNEY CORP., 3929 WESTPOINT BLVD., SUITE G, WINSTON-SALEM NC 27103
Jennifer A. Fox	director	C/O NUVATION BIO INC., 1500 BROADWAY, SUITE 1401, NEW YORK NY 10036
Timothy Bertram	director, officer: Chief Executive Officer	C/O TENGION, INC., 2900 POTSHOP LANE, SUITE 100, EAST NORRITON PA 19403